Abstract
Background: MicroRNA-19b (miR-19b) is essential in determining oligodendroglia proliferation. Phosphatase and tensin homologue on chromosome 10 (PTEN) is considered the target of miR-19b and participates in oligodendrocyte differentiation and proliferation.
Methods: Murine EAE was induced by myelin oligodendrocyte glycoprotein (MOG35– 55). For EAE reversal, artificially synthesized agomiR-19b was intravenous injected after immunization.
Results: We found that the expression of miR-19b is significantly reduced in an experimental autoimmune encephalomyelitis (EAE) mouse model. This downregulation, which is associated with the neurological scores, can be dramatically ameliorated by agomiR-19b. Our results show that agomiR-19b increases the expression of myelin basic protein (MBP) and cyclic nucleotide phosphodiesterase (CNP), which are regularly utilized as molecular markers of oligodendrocytes. Furthermore, our study also revealed that miR-19b probably affects the expression of PTEN in the EAE model.
Conclusion: These results indicate that the restoration of miR-19b probably exerts its therapeutic effect by affecting PTEN in the pathogenesis of EAE.
Keywords: MiR-19b, experimental autoimmune encephalomyelitis, oligodendrocyte, PTEN, agomiR-19b, MBP, CNP.
Current Molecular Medicine
Title:MiR-19b Functions as a Potential Protector in Experimental Autoimmune Encephalomyelitis
Volume: 18 Issue: 5
Author(s): B. Hu, Z.L. Hu, Q.M. Zeng, B. Xiao and H. Yang*
Affiliation:
- Department of Neurology, Xiangya Hospital of Central South University, Changsha, 410008,China
Keywords: MiR-19b, experimental autoimmune encephalomyelitis, oligodendrocyte, PTEN, agomiR-19b, MBP, CNP.
Abstract: Background: MicroRNA-19b (miR-19b) is essential in determining oligodendroglia proliferation. Phosphatase and tensin homologue on chromosome 10 (PTEN) is considered the target of miR-19b and participates in oligodendrocyte differentiation and proliferation.
Methods: Murine EAE was induced by myelin oligodendrocyte glycoprotein (MOG35– 55). For EAE reversal, artificially synthesized agomiR-19b was intravenous injected after immunization.
Results: We found that the expression of miR-19b is significantly reduced in an experimental autoimmune encephalomyelitis (EAE) mouse model. This downregulation, which is associated with the neurological scores, can be dramatically ameliorated by agomiR-19b. Our results show that agomiR-19b increases the expression of myelin basic protein (MBP) and cyclic nucleotide phosphodiesterase (CNP), which are regularly utilized as molecular markers of oligodendrocytes. Furthermore, our study also revealed that miR-19b probably affects the expression of PTEN in the EAE model.
Conclusion: These results indicate that the restoration of miR-19b probably exerts its therapeutic effect by affecting PTEN in the pathogenesis of EAE.
Export Options
About this article
Cite this article as:
Hu B. , Hu Z.L., Zeng Q.M., Xiao B. and Yang H. *, MiR-19b Functions as a Potential Protector in Experimental Autoimmune Encephalomyelitis, Current Molecular Medicine 2018; 18 (5) . https://dx.doi.org/10.2174/1566524018666181004123716
DOI https://dx.doi.org/10.2174/1566524018666181004123716 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Organoselenium Compounds as Potential Neuroprotective Therapeutic Agents
Current Organic Chemistry The Cannabinoid CB2 Receptor as a Target for Inflammation-Dependent Neurodegeneration
Current Neuropharmacology The Many Roles of Chemokine Receptors in Neurodegenerative Disorders: Emerging New Therapeutical Strategies
Current Medicinal Chemistry Revolutionary Impact of Nanodrug Delivery on Neuroscience
Current Neuropharmacology Multiple Sclerosis - A Coordinated Immune Attack Across the Blood Brain Barrier
Current Neurovascular Research Role of Nitric Oxide and Reactive Oxygen Species in Arthritis
Current Pharmaceutical Design Applications of iTRAQ and TMT Labeling Techniques to the Study of Neurodegenerative Diseases
Current Protein & Peptide Science Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology Antioxidants and Neuroprotection in the Adult and Developing Central Nervous System
Current Medicinal Chemistry Mosquito and Tick-borne Illnesses in the United States. Guidelines for the Recognition and Empiric Treatment of Zoonotic Diseases in the Wilderness.
Infectious Disorders - Drug Targets Patents Relating to the Application of Autologous Bone Marrow-Derived Mesenchymal Stromal Cell and Whole Marrow Transplantation for Neurodegenerative Diseases: A Review
Recent Patents on Regenerative Medicine Atopic Dermatitis and Cytokines: The Immunoregulatory and Therapeutic Implications of Cytokines in Atopic Dermatitis - Part II: Negative Regulation and Cytokine Therapy in Atopic Dermatitis
Recent Patents on Inflammation & Allergy Drug Discovery Targeting Toll-like Receptors in Autoimmunity
Current Drug Targets The Role of T-Helper Cells in Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Role of Cytokines in Neurological Disorders
Current Medicinal Chemistry New Insights into the Modulation of Immune Response by Fasciola hepatica Excretory-Secretory Products
Current Immunology Reviews (Discontinued) Inhibitors of the Immunoproteasome: Current Status and Future Directions
Current Pharmaceutical Design Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Lipid-Based Nanocarriers for CNS-Targeted Drug Delivery
Recent Patents on CNS Drug Discovery (Discontinued) From the Molecular Mechanism to Pre-clinical Results: Anti-epileptic Effects of Fingolimod
Current Neuropharmacology